Bath Savings Trust Co lessened its holdings in shares of Balchem Co. (NASDAQ:BCPC – Free Report) by 0.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,094 shares of the basic materials company’s stock after selling 100 shares during the quarter. Bath Savings Trust Co owned approximately 0.12% of Balchem worth $5,270,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of BCPC. Wasatch Advisors LP grew its position in shares of Balchem by 27.0% in the first quarter. Wasatch Advisors LP now owns 2,069,516 shares of the basic materials company’s stock valued at $261,752,000 after purchasing an additional 439,827 shares during the last quarter. Norges Bank acquired a new position in shares of Balchem in the fourth quarter valued at approximately $40,469,000. Vanguard Group Inc. grew its position in shares of Balchem by 7.3% in the third quarter. Vanguard Group Inc. now owns 3,862,027 shares of the basic materials company’s stock valued at $469,545,000 after purchasing an additional 261,534 shares during the last quarter. Morgan Stanley grew its position in shares of Balchem by 86.1% in the fourth quarter. Morgan Stanley now owns 491,506 shares of the basic materials company’s stock valued at $60,018,000 after purchasing an additional 227,360 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Balchem by 58.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 345,020 shares of the basic materials company’s stock valued at $41,949,000 after purchasing an additional 127,686 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on BCPC shares. HC Wainwright increased their price target on Balchem from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, July 31st. StockNews.com began coverage on Balchem in a research note on Thursday, August 17th. They set a “hold” rating for the company.
Balchem Price Performance
Shares of BCPC traded down $2.39 during trading hours on Monday, reaching $132.39. The stock had a trading volume of 32,793 shares, compared to its average volume of 93,214. Balchem Co. has a 12 month low of $116.68 and a 12 month high of $143.88. The stock has a market capitalization of $4.27 billion, a PE ratio of 43.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.85 and a current ratio of 2.94. The company’s 50-day moving average is $134.43 and its two-hundred day moving average is $130.42.
Balchem (NASDAQ:BCPC – Get Free Report) last announced its quarterly earnings results on Friday, July 28th. The basic materials company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.13. Balchem had a return on equity of 10.43% and a net margin of 10.58%. The company had revenue of $231.25 million during the quarter, compared to analysts’ expectations of $241.00 million. Research analysts expect that Balchem Co. will post 3.5 EPS for the current year.
Insider Buying and Selling
In related news, Director David B. Fischer sold 3,800 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $131.57, for a total transaction of $499,966.00. Following the completion of the transaction, the director now directly owns 13,469 shares of the company’s stock, valued at approximately $1,772,116.33. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.77% of the stock is owned by corporate insiders.
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
- Five stocks we like better than Balchem
- Are Stock Buybacks Good for the Average Investor?
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- 3 Best Fintech Stocks for a Portfolio Boost
- 5 Reasons Mullen Automotive is About to Turn a Corner
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.